Blog

Federal Marijuana Rescheduling: What It Could Mean for the Cannabis Industry in 2025

Marijuana Rescheduling Law Updates The conversation around federal marijuana rescheduling is heating up in Washington again. A proposal to move cannabis from Schedule I to Schedule III under the Controlled Substances Act could reshape the industry, medical research, and tax policy across the U.S. Key Takeaways Federal marijuana rescheduling to Schedule III is under review in 2025. Could ease research barriers and remove IRS 280E limits on standard deductions. Banking restrictions likely rem …

Aug 11, 2025 Katy Price

FDA DISCLAIMER: The products on this site are not for use by or sale to persons under the age of 18 or 21 depending on the laws of your governing state or territory. The statements made regarding these products have not been evaluated by the Food and Drug Administration. The efficacy of these products has not been confirmed by the FDA-approved research. These products are not intended to diagnose, treat, cure or prevent any disease. Please consult your health care professional about potential interactions or other possible complications before using any product. The Federal Food, Drug, and Cosmetic Act requires this notice.

By using this site you agree to follow the Privacy Policy and all Terms & Conditions printed on this site. Void where prohibited by law.
Disclaimer: We will not ship any of our Delta, THC, or Kratom products to states or counties where such products are illegal.